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IL-17–producing CD4
 T cells (Th-17) contribute to
the pathogenesis of experimental autoimmune en-
cephalomyelitis and are associated with active disease
in multiple sclerosis (MS). In addition to IL-17, Th-17
cells can also express IL-21, IL-22, and IL-6 under
Th-17–polarizing conditions (IL-6 and transforming
growth factor-). In this study we investigated IL-21
and IL-21 receptor (IL-21R) expression in MS lesions
by in situ hybridization and immunohistochemistry.
We detected strongly IL-21
 infiltrating cells predom-
inantly in acute but also in chronic active white mat-
ter MS lesions in which IL-21 expression was re-
stricted to CD4
 cells. In contrast, IL-21R was much
more broadly distributed on CD4
, CD19
, and CD8

lymphocytes but not major histocompatibility com-
plex class-II
 macrophages/microglia. Interestingly,
in cortical areas we detected both IL-21 and IL-21R
expression by neurons. These findings suggest role(s)
for IL-21 in both the acute and chronic stages of MS
via direct effects on T and B lymphocytes and, dem-
onstrated for the first time, also on neurons. (Am J
Pathol 2011, 178:794–802; DOI: 10.1016/j.ajpath.2010.10.043)
Multiple sclerosis (MS) is the most common neuro-inflam-
matory demyelinating disease of the central nervous system
(CNS), and it affects both the white and gray matter. White
matter lesions are characterized by inflammatory infiltration,
demyelination and gliosis, with axonal loss, whereas cortical
lesions are characterized by demyelination and modest
neuronal loss.
1 Interleukin-17 (IL-17)–producing CD4
 T
cells (Th-17) cells play important roles in the pathogenesis
of experimental autoimmune encephalomyelitis (EAE), an
animal model of MS,
2 and are also found at high frequency
in active MS lesions.
3 However, because IL-17 cytokines
seem to be only partially involved in the development of
EAE,
4,5 other concomitant Th-17 cell products may contrib-
ute to the disease process and thus demand investigation.
They include IL-6,
4 IL-21,
6 and IL-22.
7 IL-6 is implicated
because EAE was prevented either by its genetic deletion
8
or by monoclonal antibody blockade of its receptor.
9 In MS,
IL-6 has been detected predominantly in astrocytes and
some macrophages at sites of ongoing demyelination
10
and also in inactive plaques.
11 By contrast, the mainly mu-
cosal IL-22 does not appear to be directly involved in the
pathogenesis of EAE, because IL-22 knock-out mice are
fully susceptible.
7
Involvement of IL-21 in EAE is controversial; its adminis-
tration before EAE induction leads to NK cell activation and
exacerbated disease,
12 and other studies have shown that
IL-21 also leads to Th-17 activation and IL-17 expression in
vitro.
13,14 However, blockade of IL-21 before or after EAE
induction reportedly accelerated EAE, with more severe
inflammatory infiltration, because of reduction of regulatory
T cells.
15,16 Studies in IL-21 and/or IL-21 receptor (IL-21R)
knock-out mice have also yielded apparently conflicting
evidence as to the role of IL-21 in EAE. In one study, the
absence of IL-21 prevented Th-17 cell activation and ame-
liorated EAE
6; however, in three subsequent studies in IL-
21
/ and/or IL-21R
/ mice, IL-21 was not required for
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794disease promotion and may even have partially protected
against EAE.
15,17,18
IL-21 expression has not yet been studied in MS CNS
tissue, but studies examining T-cell clones derived from
patients with MS have identified a subset of myelin basic
protein–specific T cells with a pro-inflammatory phenotype
that express IL-21.
19 In addition, polymorphisms in IL-21R
showed associations in EAE and MS in a recent genetic
study.
20 IL-21 polymorphisms have been associated with
systemic lupus erythematosus
21 and diabetes mellitus,
whereby a polymorphism in the IL-21R was also studied.
22
Expression studies have shown that IL-21 is up-regulated in
gastrointestinal inflammation, notably in Crohn’s and celiac
diseases.
23,24 Taken together, these studies strongly impli-
cate IL-21 in several autoimmune diseases, including MS.
Here, we present the first study on the expression of
IL-21/IL-21R mRNA and protein in acute, chronic, and
inactive MS lesions by in situ hybridization and immuno-
histochemistry. We show expression of IL-21 by the ma-
jority of CD4
 T cells and of IL-21R by the majority of T
and B cells in acute and chronic MS lesions. We therefore
propose direct and pleiotropic roles of IL-21 in MS patho-
genesis. We also detected expression of IL-21 and IL-
21R in neurons in the cortical gray matter, which may
implicate IL-21 in modulating neuronal responses to in-
flammation and neuronal injury, an observation that war-
rants further exploration.
Materials and Methods
Tissue Specimens
All brain tissues were obtained with informed consent and
Research Ethics Committee approval from the UK Multiple
Sclerosis Tissue Bank, the Thomas Willis Oxford Brain Col-
lection, and NeuroResource, UCL Institute of Neurology.
Both paraffin and frozen brain tissues (see Supplemental
Tables S1 and S2 at http://ajp.amjpathol.org) were used for
this study, obtained at autopsy from patients with MS (25
cases, 36 blocks) and control patients with other neurologic
diseases [13 cases, 13 blocks; subacute sclerosing pan-
encephalitis (SSPE), Herpes simplex encephalitis (HSE),
acute disseminated encephalomyelitis (ADEM), and stroke]
or nonneurologic diseases (8 cases, 9 blocks). We typed
white matter lesions by staining with oil red O (ORO; for
frozen tissue) or for paraffin-embedded tissue, Luxol fast
blue (LFB), anti–major histocompatibility complex (MHC)
class II and H&E to identify the centers and borders of the
lesions, their activity, hypercellularity (inflammatory cell infil-
tration), and areas of hypocellularity (loss of parenchymal
cells in inactive lesions). In all cases, the clinical diagnosis
had been made during life and confirmed neuropathologi-
cally at autopsy.
Lesions were classified into three groups: i) acute lesions
with hypercellularity due to infiltration with lymphocytes and
numerous macrophages (frozen tissue: macrophages
staining strongly with ORO; paraffin-embedded tissue:
macrophages staining with LFB or for anti–proteolipid pro-
tein); ii) chronic active lesions, typically with hypercellular
active borders with strongly staining ORO
 or LFB
 mac-
rophages and demyelinated hypocellular/inactive centers
with very few ORO
 or LFB
 macrophages; iii) inactive
lesions, characteristically showing demyelination, severe
hypocellularity due to the significant loss of parenchymal
cells, and only minimal inflammatory infiltration staining neg-
ative with ORO or LFB.
In Situ Hybridization
IL-21R and IL-21 oligoprobes were obtained from Exiqon
labeled with Digoxigenin.
25 Sections were processed for
in situ hybridization cytochemistry as previously de-
scribed.
26 In brief, frozen tissue sections (10 m) were
fixed for 11 minutes with 4% paraformaldehyde followed
by treatment with proteinase K (Sigma-Aldrich, Dorset,
UK) for 20 minutes at room temperature under RNase-
free conditions. Hybridization was performed overnight at
56°C with the digoxigenin-3=–coupled IL-21R linked nu-
cleic acid oligoprobe (5=-GAGCGCCAGGAGATAT-
TATACTGT-3=) and at 54°C with the digoxigenin-3-5=–
coupled IL-21 linked nucleic acid oligoprobe (5=-
ATGAAGGGCATGTTAGTCTGTGTT-3=). After washing,
the sections were incubated with antidigoxigenin alkaline
phosphatase–conjugated Fab fragments (1:2000; Roche
Diagnostics) overnight at 4°C and visualized with the use
of Nitro-Blue Tetrazolium Chloride/5-Bromo-4-Chloro-3=-
Indolyphosphate p-Toluidine Salt (Roche Diagnostics)
chromogenic reaction. Positive controls with fresh frozen
tonsil showed specific signals in lymphocytes and epi-
thelial cells (data not shown). As a negative control, a
digoxigenin-3=–coupled non-complementary linked nu-
cleic acid oligoprobe (5=-GTGTAACACGTCTATACGC-
CCA-3=) was used under the same conditions as the
IL-21 and IL-21R linked nucleic acid oligoprobes on fresh
frozen tonsil (data not shown) and consecutive sections
of MS brains (Figures 1B, 4B, 5C, and 6C).
Immunohistochemistry
Paraffin-embedded sections (6 m thick) were deparaf-
finized followed by hydration with graded alcohol solutions.
Endogenous peroxidase was blocked by incubation with
0.75% hydrogen peroxide for 15 minutes, followed by antigen
unmasking with the use of heated citrate buffer (pH, 6). Sec-
tions were stained with mouse anti–IL-21 (1/400; 1F1A2B2C2;
Novo Nordisk, Denmark). Slides were developed with the En-
vision kit by incubation for 1 hour at room temperature with the
horseradish peroxidase anti-rabbit/mouse complex (Dako,
Cambridgeshire, UK) as described by the manufacturer.
Staining was performed with diaminobenzidine (Dako) as
chromogenic substrate for up to 5 minutes.
For double labeling, we used anti–IL-21 mouse monoclo-
nal or IL-21R rabbit polyclonal (ab13268; Abcam) antibod-
ies, followed by staining with the Tyramide Signal Amplifi-
cation kit with Alexa Fluor 488–anti-mouse IgG (Invitrogen,
Paisley, UK). For IL-21 staining, sections were blocked with
anti-mouse IgG antibody (1/200) to prevent background
staining. After washing, slides were then incubated over-
night with the following sequential primary antibodies:
mouse anti-CD4 (1/10; 4B12; Novocastra, UK), mouse anti-
CD8 (1/20; kindly donated by Dr Margaret Jones, John
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acidic protein (1/1000; DAKO), sheep anti-carbonic anhy-
drase isoenzyme II (1/300; Serotec), rat anti-MHC class II
(1/100; Serotec), or mouse anti-microtubule associated pro-
tein (1/200; M-1406; Sigma, UK). Appropriate secondary
antibodies included Cy3 anti-rat Ig (1/100; Jackson Labo-
ratory, Suffolk, UK) and Alexa Fluor 568–anti-rabbit (1/200)
or anti-sheep Ig (1/200; both Invitrogen) for 4 hours. As
negative controls for each second layer in sequential stain-
ings, the same procedure as mentioned previously was
followed except that the sequential primary antibodies were
omitted. No staining was seen in these sections appropriate
to the sequential secondary antibody.
Data Acquisition
Areas of different activity as defined above were used for
quantitation, from acute, chronic active, and inactive le-
sions and from control brains (see Supplemental Table
S1 at http://ajp.amjpathol.org). Digital images of tissue
sections were captured with an Olympus light micro-
scope BX41 and a Zeiss camera (Zeiss, Thornwood, NY).
Multiple images of different perivascular cuffs were ac-
quired, and their areas were calculated by the Axion
Image software (Zeiss). IL-21
 cells with lymphocytic
morphology were counted by eye within predefined ar-
eas of each perivascular cuff, and their densities were
expressed per mm
2. In each lesion, three to six cuffs with
a total area 2  10
5 m
2 were counted. To investigate
colocalization of IL-21 or IL-21R proteins with lymphocyte
subpopulations (CD4
 T cells, and of IL-21R with CD4

or CD8
 T cells and CD19
 B cells), multiple images
were acquired with the use of a confocal microscope
(Bio-Rad, Hercules, CA). For counting percentages of
CD4
 cells in lesion areas of different activity, multiple
images were taken from all of the cuffs, and their cells
were counted with ImageJ software. To quantify and
Figure 1. IL-21 is predominantly expressed in acute and chronic active MS
lesions. A: High-magnification image of IL-21 mRNA expression in an active
border of a chronic active MS lesion visualized by in situ hybridization with
the use of a specific probe for IL-21. B: Negative control that used a scram-
bled oligoprobe on a consecutive section from the same cuff. C-F: Light
microscopy analysis of IL-21 immunostaining in perivascular cuffs of lesions
with different activity. C: Acute lesion, (D) active border of a chronic active
lesion, (E) inactive center of a chronic active lesion, (F) an inactive lesion.
Scale bars  30 m. G: Density of IL-21
 cells in MS lesions of different
activity. There is a statistically significant difference of *P  0.05 between the
density of IL-21
 cells in inactive lesions and in each of the other lesion
types.
Figure 2. IL-21 expression in other neuro-inflammatory diseases. IL-21 ex-
pression was not detected lymphocytes within control brain (A). In the
neuro-inflammatory conditions of SSPE (B) and HSE (C), significant numbers
of IL-21
 lymphocytes were observed in perivascular spaces. Surprisingly, in
ADEM (four cases), few, if any, IL-21
 lymphocytes were observed (D). In
stroke (E), few IL-21
 lymphocytes were observed in perivascular spaces,
but high infiltration of IL-21
 lymphocytes in the parenchyma of the white
and gray matter was observed. F: An acute MS lesion is shown for compar-
ison (same as in Figure 1). Scale bar  50 m.
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gray matter cortical areas from MS tissue cases and
controls were measured, taking images of neurons and
calculating the intensity of signal via semiquantitative mi-
crodensitrometry with the use of ImageJ software.
Statistical Analysis
Statistical significances were calculated with Student’s
t-test for unequal variances and single analysis of vari-
ance with multiple comparisons (Tukey’s test) as appro-
priate. Data are presented as mean  SEM. P value 
0.05 denotes statistically significant differences.
Results
Most CD4
 T Cells Infiltrating Active MS
Lesions Are IL-21

We first studied the expression of IL-21 mRNA and protein
in MS lesions. In white matter lesions, IL-21 mRNA expres-
sion was detected specifically in perivascular cells, which
showed the disposition and morphology typical of lympho-
cytes (Figure 1A). Next, we compared IL-21 mRNA expres-
sion in lesions of different activity and also confirmed our
findings independently by staining for IL-21 protein in an
overlapping series of samples. We observed high densities
of IL-21
 cells within perivascular areas, whether in acute
MS lesions (Figure 1C), active borders of chronic active MS
lesions (Figure 1D), or their inactive interiors (Figure 1E).
However, the densities of IL-21
 cells (Figure 1F) were
significantly higher in acute (P  0.01) or chronic active
(P  0.03) than in inactive MS lesions; in the latter, they did
not differ significantly between the active borders and inac-
tive interiors (P  0.21) (Figure 1G). In control white matter,
no IL-21
 lymphocytes were detected.
Interestingly, we also found significant numbers of
perivascular IL-21
 cells in two other neuro-inflammatory
conditions, SSPE (Figure 2B) and HSE (Figure 2C). By
contrast, in stroke (Figure 2E), infiltrating IL-21
 cells
were seen mostly in the ischemic parenchyma of the
white and gray matter, suggesting a possible role of IL-21
in inflammatory/ischemic-mediated tissue injury. Interest-
ingly, in ADEM (Figure 2D), an acute monophasic neuro-
inflammatory disease with abundant CD4
 T-cell lympho-
cytes in perivascular cuffs,
27 few, if any, IL-21
 cells were
observed in any of the four cases, suggesting different
pathogenic mechanisms.
28
IL-21 Is Restricted to CD4
 Cells and Is Associated
with Acute and Chronic Active MS Lesions
We next identified the immune cell subpopulations ex-
pressing IL-21 in MS lesions, by co-staining for CD4

(Th; Figure 3, A–C)o rC D 8
 (cytotoxic) T cells (Figure 3,
D–F), CD19
 (B cells; Figure 3, G–I), and MHC class II

cells (microglia/macrophages; Figure 3, J–L). Among
these, IL-21 expression was restricted to CD4
 cells and
not observed in CD8
, CD19
, or MHCII
 cells (Figure
3). Approximately 67% to 75% of the CD4
 cells were
IL-21
 in acute and in both active borders and interiors of
chronic active MS lesions but in only 26% of CD4
 T cells
in inactive lesions (P  0.01; Table 1). These data show
Figure 3. IL-21 is restricted to CD4
 cells in acute MS lesions. A high
percentage of CD4
IL-21
 cells are associated with acute and chronic active
MS lesions but not with inactive lesions. Double-immunofluorescence stain-
ing in the perivascular space of active areas of MS lesions was analyzed by
confocal microscopy for IL-21 staining (B, E, H, and K; green), CD4
 (A;T h
cells, red), CD8
 (D; cytotoxic lymphocytes, red), CD19
 (G; B lymphocytes,
red), and MHCII
 (J; macrophages/microglia). The overlays (C, F, I, and L)
show specific expression of IL-21 in CD4
 cells in panel C (but not in the
other cell types). Scale bar  20 m.
Table 1. CD4
 Cells Predominantly Express IL-21 in Acute and Chronic Active MS Lesions
MS lesion category
Acute
(%  SEM)
Chronic active (border)
(%  SEM)
Chronic active (inside)
(%  SEM)
Inactive
(%  SEM)
CD4
 cells that are IL-21
 75.3  4.6 73.8  4.7 66.8  4.3 26  6.4*
For each lesion category, three to five lesions with 75  20 cells/area were measured (see Supplemental Figure S1 at http://ajp.amjpathol.org). Higher
percentages of IL-21
CD4
 T cells within active and chronic active lesions are shown, in contrast to inactive lesions in which there is a low frequency of
IL-21
CD4
 cells.
*P  0.001.
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 T cells express IL-21 in the
acute (acute lesions) and chronic (chronic active lesions)
phases of MS, and this proportion declines only in inac-
tive MS lesions (P  0.01). As observed with single im-
munostaining (see above), there was no difference in the
percentage of IL21
CD4
 cells between the active bor-
ders and the inactive interiors of chronic active lesions
(P  0.693). These findings suggest that IL-21 plays a
role in maintaining a pro-inflammatory environment in
chronic active MS lesions.
IL-21R Is Highly Expressed in CD4
 and CD8

T Cells and in CD19
 B Cells in Acute and
Chronic Active MS Lesions
Next, we checked for cells capable of responding to
IL-21 via its cognate receptor. In situ hybridization and
immunohistochemistry detected strong signals for IL-21R
mRNA and protein, respectively, in white matter MS le-
sions, specifically in perivascular cells (again showing
typical lymphocytic disposition and morphology), pre-
dominantly in active areas of acute and chronic active MS
lesions (Figure 4A). With the use of double-labeling im-
munohistochemistry in MS lesions showed IL-21R label-
Figure 4. High expression of IL-21R on CD4
 and CD8
 T cells and CD19

B cells in acute and chronic active MS lesions. A: Perivascular cuff showing
high expression of IL-21R mRNA in perivascular lymphocytes in an active
area of a white matter MS lesion. B: Negative control that used the scrambled
oligoprobe in a consecutive section. Double-immunofluorescence staining in
the perivascular region of active areas of MS lesions was analyzed by con-
focal microscopy for IL-21R expression (D, G, J, and M; green) in CD4
 (C;
Th cells, red), CD8
 (F; cytotoxic lymphocytes, red), CD19
 (I; B lympho-
cytes, red), and MHCII class II (L; macrophages/microglia, red). The overlays
(E, H, K, and N) show expression of IL21R in CD4
 (E), CD8
 (H), and
CD19
 lymphocytes (K) and no expression in MHCII
 macrophages/micro-
glia (N). Scale bars  20 m.
Figure 5. IL-21 mRNA and protein expression in cortical areas from MS and
control brain. A–C: In situ hybridization with a specific probe for IL-21. MS
(A), normal (B); negative control with the use of a non-complementary
oligoprobe on a consecutive section of the MS tissue (C). D–I: Double
immunofluorescence staining analyzed by confocal microscopy staining for
IL-21 (E and H; green), MAPII (microtubule associated protein) (D and G; for
neurons, red), taken from cortical areas from MS (D–F) and normal brain
(G–I). Overlays show a similar degree of IL-21 staining in MS and normal
brain. Scale bars: 30 m( A–C); 10 m( D–I). J: Semiquantitative microden-
sitometry of IL-21
 neurons in MS cortical neurons and normal control tissue.
The difference in IL-21 intensity between normal and MS brains is not
statistically significant (P  0.05).
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 (Figure 4, C–E), CD8
 (Figure 4, F–H), and
CD19
 (Figure 4, I–K) cells, but not on MHC class II

macrophages/microglia (Figure 4, L–N). Specifically, in
the case of CD4
 cells, IL-21R was detected in approx-
imately 75% to 79% of the cells in acute, active border
and within chronic active MS lesions versus only 40% in
inactive lesions (P  0.05; Table 2). We noted parallel
proportions of IL-21R
 CD8
 and CD19
 cells within
active MS lesions (Table 2), although the reduction in
CD8
 cells within inactive MS lesions did not achieve
significance (P  0.05).
IL-21 and IL-21R Are Expressed in Neurons in
the Gray Matter and Appear Up-Regulated in
MS Lesions
Because cytokines and cytokine receptors have been
detected previously in neuronal
29 and glial cells,
30 we
checked for IL-21 and IL-21R expression by these cells in
MS and control brains. Interestingly, in cortical areas of
postmortem MS tissue and control brains in situ hybrid-
ization showed active synthesis of both IL-21 (Figure 5,
A–C) and IL-21R (Figure 6, A–C) in cells with neuronal
morphology. This was further verified at the protein level
with double immunofluorescence in cortical areas show-
ing IL-21 (Figure 5, A–I) and IL-21R (Figure 6, A–I) in cells
co-labeling for the neuronal marker microtubule associ-
ated protein. Astrocytes and oligodendrocytes were neg-
ative for both IL-21 and IL-21R in MS cortical tissue by in
situ hybridization and fluorescence immunohistochemis-
try (data not shown) (see Supplemental Figure S1 at
http://ajp.amjpathol.org).
On semiquantitative microdensitometry, we noted 34%
stronger neuronal IL-21 protein labeling of cortical neu-
rons in MS than in control tissue, but the difference was
not significant (P  0.05). Interestingly, expression of
IL-21R was more than twofold higher in MS than in control
cortical neurons (P  0.05). These findings suggest po-
tential roles for IL-21 both in mediating responses by
nonimmune cells and in tissue injury in MS lesions.
Discussion
The present study showed that IL-21 expression was not
detectable in control white matter but was significantly
greater in the CD4
 lymphocytes infiltrating acute and
chronic active lesions than in inactive lesions (Figures 1
and 2), suggesting that it plays pro-inflammatory role(s)
Figure 6. IL-21R mRNA and protein expression in cortical areas from MS
and normal brain. A–C: In situ hybridization with a specific probe for
IL-21R. A: MS, (B) control; (C) negative control with the use of a non-
complementary oligoprobe on a consecutive section of the MS tissue.
D–I: Double immunofluorescence staining analyzed by confocal micros-
copy staining for IL-21R (E and H; green), MAPII (microtubule associated
protein) (D and G; for neurons, red), taken from cortical areas from MS
(D–F) and control brain (G–I). Overlays (F and I) show a similar degree
of IL-21R staining in MS and control brain. Scale bar: 30 m( A–C); 15 m
(E–M). J: Semiquantitative microdensitometry of IL-21R
 neurons in MS
cortical neurons and control tissue. *P  0.05. IL-21R intensity between
normal and MS brains.
Table 2. IL-21R Is Predominantly Expressed in CD4
, CD8
, and CD19
 Cells in Acute and Chronic Active MS Lesions
MS lesion category
Cell type Acute Chronic active (border) Chronic active (inside) Inactive
CD4
 76.5  5.3 76  2.5 79.2  5.3 40  5.7*
CD8
 63.3  7.1 60.6  7.6 51.2  7.8 34.3  7
CD19
 68.3  5.1 67  7.5 59  8.2 24  1*
For each cell type within a lesion category, three to five lesions with 45  4 cells/area were measured (see Supplemental Table S1 at http://
ajp.amjpathol.org). Values are percentage ( SD) of IL-21R
 cells.
*P  0.05.
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sufficient to stratify these results not only by lesion clas-
sification but also by the clinical course of the disease.
Comparable white matter infiltrates of IL-21
 cells in MS
were also observed in SSPE and HSE, suggesting a
similar role of IL-21 in these neuro-inflammatory CNS
diseases (Figure 3). In intriguing contrast, IL-21
 inflam-
matory cells were unexpectedly rare in ADEM, an acute
monophasic neuro-inflammatory demyelinating dis-
ease.
31 This difference suggests that IL-21 is involved in
the maintenance of chronic more than acute inflammation
in the brain
32 and also in psoriatic skin.
33 Similarly, it
seems that Th-17 cells producing IL-21 are not involved
in the pathogenesis of ADEM, but they seem to be more
important for MS. This is supported by the finding that
IL-17 is not increased in the cerebral spinal fluid (CSF) of
patients with ADEM,
34 whereas elevated levels can be
found in the CSF of patients with early MS.
35
Moreover, we also demonstrated a significant increase
in IL-21R expression within cortical neurons in MS brains,
possibly implicating it in modulating neuronal responses/
injury. We noted a further striking contrast with the inflam-
matory pathologies in cerebral infarcts. The IL-21
 cells
here were widely distributed in the ischemic parenchyma
and were not confined to the perivascular spaces, but
they even reached cortical areas, again suggesting that
IL-21 might affect neurons. In addition, this detection of a
Th-17 cell-related cytokine, IL-21, in SSPE, HSE, and
stroke suggests that other cytokines expressed from
Th-17 cells, such as IL-17, IL-22, or IL-26,
36 may be
involved in these diseases. In fact, lymphocytes express-
ing IL-17 have been recently detected in stroke.
29
In vitro studies of IL-21 have shown pleiotropic func-
tions, depending on the activation state of the target cells
studied.
37,38 Its restriction to CD4
 T cells mainly in
perivascular localization in active regions of white matter
lesions in MS, together with the expression of IL-21R on
the adjacent CD4
, CD8
, and CD19
 cells (Figure 4),
suggests that IL-21 exerts widespread pro-inflammatory
influences in MS. IL-21R was not expressed in microglia/
macrophages in MS lesions, unlike in rheumatoid syno-
vium,
39 which implies additional specific microenviron-
mental influences. These novel findings suggest that
IL-21 preferentially influences T- and B-cell responses,
thus making it an important focus for potential therapeutic
interventions in MS. Indeed, recent studies in mice and
humans have implicated IL-21 as an important mediator
of autoimmune responses
40 and in preventing exhaustion
of protective CD8
 lymphocytes in chronic viral infec-
tions.
32 Thus, unlike the shorter-lived IL-17,
3 IL-21 may
help to sustain pathogenic responses in MS. Indeed, it
apparently contributes to autoimmunity by driving cycles
of T-cell expansion and death to excess, increasing the
probability of generating self-reactive T cells.
40 By con-
trast IL-6, another important Th-17–polarizing cytokine,
which is also expressed by Th-17 cells, was primarily
detected in inactive MS lesions expressed by astro-
cytes.
11 This might indicate that IL-21 produced by Th17
cells is more important than IL-6 for inflammatory activi-
ties in active lesions.
Initial studies on human and murine tissues (including
CNS tissue) showed IL-21 and IL-21R transcripts only in
lymphoid tissue and peripheral blood lymphocytes.
41 How-
ever, later studies reported IL-21R expression in fibroblasts
from patients with rheumatoid arthritis
39 or inflammatory
bowel disease or from healthy controls,
37 and also in kera-
tinocytes from patients with systemic sclerosis.
42 In the
present study, the clear neuronal expression of IL-21 and
IL-21R in neuronal cells in control and MS brains, newly
shown here (Figures 5 and 6), suggests potential for the
direct modulatory effects of cytokines on growth, differenti-
ation, and plasticity that are becoming increasingly evident
in the nervous system.
43 Such effects have been observed
with IL-2,
44 which shares with IL-21 both a common recep-
tor  chain and a common Janus kinase, signal transducer
and activator of transcription 1/signal transducer and acti-
vator of transcription 3 activation pathway. If they extend to
IL-21, they might contribute to the reported reductions in
both neuronal size and density in MS gray matter.
45 How-
ever, damaging effects of IL-21 on neurons cannot be ex-
cluded. Lymphocytic infiltration of the MS cortex is not con-
spicuous
46; the meninges, and leucocortical lesions that
span the deeper layers of the cortex, and the subcortical
white matter do contain lymphocytes,
45 which may provide
a local source of IL-21. In addition to neuronal synthesis,
IL-21 might be transported to neuronal cell bodies from
white matter lesions where their axons have been dam-
aged. As mentioned previously, numerous IL-21
 cells
were detected within and near the cortex in stroke; they
might contribute to the fate of neurons during disease pro-
gression, asrecently proposed for IL-17 in neurons in humans
and mice, where it correlates directly with neurotoxicity.
29,47
In summary, we have demonstrated for the first time
the presence and possible role of IL-21 in both CNS white
and gray matter in MS. In white matter MS lesions, abun-
dant expression of IL-21 was seen in perivascular lym-
phocyte infiltrates both in acute lesions and during pro-
gression in chronic active lesions; it might have direct
effects on both T and B lymphocytes, which both express
IL-21R. The unexpected but significant up-regulation of IL-
21R expression in neurons within MS tissue implies a role in
the neuronal injury and subsequent neurodegeneration that
are responsible for most of the disability in MS.
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